Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme: orme

Research output: Contribution to journalReview articlepeer-review

102 Citations (Scopus)
291 Downloads (Pure)


The malignant brain cancer, glioblastoma multiforme (GBM), is heterogeneous, infiltrative, and associated with chemo- and radioresistance. Despite pharmacological advances, prognosis is poor. Delivery into the brain is hampered by the blood-brain barrier (BBB), which limits the efficacy of both conventional and novel therapies at the target site. Current treatments for GBM remain palliative rather than curative; therefore, innovative delivery strategies are required and nanoparticles (NPs) are at the forefront of future solutions. Since the FDA approval of Doxil® (1995) and Abraxane (2005), the first generation of nanomedicines, development of nano-based therapies as anti-cancer treatments has escalated. A new generation of NPs has been investigated to efficiently deliver therapeutic agents to the brain, overcoming the restrictive properties of the BBB. This review discusses obstacles encountered with systemic administration along with integration of NPs incorporated with conventional and emerging treatments. Barriers to brain drug delivery, NP transport mechanisms across the BBB, effect of opsonisation on NPs administered systemically, and peptides as NP systems are addressed.

Original languageEnglish
Pages (from-to)304–318
JournalDrug Delivery and Translational Research
Early online date14 Nov 2019
Publication statusPublished - 01 Apr 2020


Dive into the research topics of 'Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme: orme'. Together they form a unique fingerprint.

Cite this